CALCA and migraine disorder: After pooling, the change in ≥50% reduction in migraine days per month from baseline to endpoint was remarkably greater for CGRP mAbs compared to placebo (RR = 1.51, 95% CI = [1.37, 1.66], I2 = 48%, p < 0.00001).